Abstract
BackgroundTo evaluate the efficacy and safety of telbivudine in chronic hepatitis B women during the second and third trimesters of pregnancy.MethodsThe week 12–34 of pregnant women were screened in this prospective non-intervention study, with HBV DNA > 106 IU/mL and alanine aminotransferase > 50 IU/L. The patients were received telbivudine treatment as a treatment group or without antiviral treatment as a control group. All infants were received recombinant hepatitis B vaccine 10 μg within 12 h of birth, at week 4 and week 24, immunoglobulin G within 12 h of birth and were detected HBV markers at the range from 7 to 12 months after delivery.ResultsA total of 241 patients were finally enrolled, 139 patients in telbivudine group and 102 patients in control group. HBsAg negative rate of infants was 99.3% (135/136) in telbivudine group and was 91.9% (91/99) in control group after 7 months (P = 0.005), respectively. The incidence of undetectable HBV DNA levels (47.5%) was significantly lower in telbivudine-treated mothers than that in the controls (0%), and 75.5% patients alanine aminotransferase returned to normal in telbivudine group, and 51% in control group at delivery (P < 0.001), respectively.ConclusionsTelbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation.
Highlights
To evaluate the efficacy and safety of telbivudine in chronic hepatitis B women during the second and third trimesters of pregnancy
The regions of the world where hepatitis B virus (HBV) genotype C is found as mother-to-child transmission (MTCT) is associated with high maternal viral load (HBV DNA > 106 IU/mL), and may occur in up to 90% of mothers who are hepatitis B surface antigen (HBsAg) positive and hepatitis B e antigen (HBeAg) positive in the
Three patients started antiviral treatment at weeks, 1 patient started at weeks, 5 patients started at weeks, 5 patients started at weeks, 4 patients started at weeks, 2 patients started at weeks, 8 patients started at weeks, 5 patients started at weeks, 4 patients started at weeks, 9 patients started at weeks, 5 patients started at weeks, 7 patients started at weeks, 2 patients started at weeks, 6 patients started at weeks, 9 patients started at weeks, 4 patients started at weeks, 18 patients started at weeks, 8 patients started at weeks, 8 patients started at weeks, 6 patients started at weeks, 8 patients started at weeks, 5 patients started at weeks, 7 patients started at weeks, respectively
Summary
To evaluate the efficacy and safety of telbivudine in chronic hepatitis B women during the second and third trimesters of pregnancy. The weighted prevalence of hepatitis B surface antigen (HBsAg) for Chinese population aged 1–59 years were 7.2%, immunization program should be further strengthened to reach those remaining at highest risk [1]. Perinatal or mother-to-child transmission (MTCT) is the most common form of transmission of hepatitis B virus (HBV) in many high-prevalence areas, in Asian countries. The regions of the world where HBV genotype C is found as MTCT is associated with high maternal viral load (HBV DNA > 106 IU/mL), and may occur in up to 90% of mothers who are HBsAg positive and hepatitis B e antigen (HBeAg) positive in the (HBIG) considerably reduced perinatal transmission [10]. No perinatal transmission has been reported in infants born to mothers with viral loads < 6 log copies/mL in other studies [6, 11]. The HBV DNA threshold to consider antiviral therapy to prevent perinatal transmission is > 2 × 105 IU/mL [9]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
